$LFMD
LifeMD, Inc. Stock $lfmd

$lfmd Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223008560 Filed on March 22, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$33.13M	$28.12M	$119.0M
YoY Change	14.06%	2.56%	28.16%
Cost Of Revenue	$4.215M	$4.068M	$18.67M
YoY Change	-19.69%	-26.94%	3.74%
Gross Profit	$28.91M	$24.05M	$100.4M
YoY Change	21.5%	10.08%	34.03%
Gross Profit Margin	87.28%	85.53%	84.32%
Selling, General & Admin	$27.32M	$27.98M	$125.3M
YoY Change	-22.71%	-17.98%	0.3%
% of Gross Profit	94.5%	116.32%	124.87%
Research & Development	$1.184M	$1.019M	$2.970M
YoY Change	176.33%	196.77%	281.4%
% of Gross Profit	4.09%	4.24%	2.96%
Depreciation & Amortization	$47.65K	$1.240M	$161.9K
YoY Change	-91.02%	256.69%	-81.37%
% of Gross Profit	0.16%	5.15%	0.16%
Operating Expenses	$31.76M	$25.81M	$143.8M
YoY Change	-13.92%	-27.33%	11.33%
Operating Profit	-$2.853M	-$1.756M	-$43.45M
YoY Change	-78.23%	-87.15%	-19.99%
Interest Expense	$264.5K	-$843.5K	$1.276M
YoY Change	-257.49%	449.29%	-142.25%
% of Operating Profit
Other Income/Expense, Net		-$2.487M
YoY Change
Pretax Income	-$3.442M	-$11.21M	-$44.66M
YoY Change	-74.07%	-37.69%	-27.16%
Income Tax		$360.7K	$360.7K
% Of Pretax Income
Net Earnings	-$4.008M	-$12.71M	-$45.54M
YoY Change	-69.8%	-29.81%	-25.23%
Net Earnings / Revenue	-12.1%	-45.21%	-38.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.15	-$0.40	-$1.57
COMMON SHARES
Basic Shares Outstanding	31.89M shares	31.45M shares	30.98M shares
Diluted Shares Outstanding	31.68M shares		30.98M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.52M	$3.959M	$3.959M
YoY Change	-54.06%	-90.42%	-90.42%
Cash & Equivalents	$11.52M	$3.959M
Short-Term Investments
Other Short-Term Assets	$1.074M	$687.0K	$814.3K
YoY Change	-26.35%	-13.38%	-18.31%
Inventory	$3.383M	$3.703M	$3.703M
Prepaid Expenses
Receivables	$2.937M	$2.835M	$2.835M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.16M	$11.31M	$11.31M
YoY Change	-35.21%	-74.82%	-74.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$462.4K	$476.4K	$1.682M
YoY Change	-78.39%	103.78%	-15.3%
Goodwill	$0.00	$0.00
YoY Change	-100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.71M	$14.35M	$14.35M
YoY Change	-29.0%	186.99%	186.99%
TOTAL ASSETS
Total Short-Term Assets	$19.16M	$11.31M	$11.31M
Total Long-Term Assets	$14.71M	$14.35M	$14.35M
Total Assets	$33.87M	$25.67M	$25.67M
YoY Change	-32.65%	-48.59%	-48.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.903M	$10.11M	$10.11M
YoY Change	-40.88%	11.56%	11.56%
Accrued Expenses	$11.58M	$12.17M	$10.25M
YoY Change	-4.21%	4.92%	10.89%
Deferred Revenue		$5.500M
YoY Change		266.67%
Short-Term Debt	$1.822M	$2.797M	$2.797M
YoY Change	2774.59%	4312.07%	4312.07%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.02M	$31.37M	$31.37M
YoY Change	5.49%	37.45%	37.45%
LONG-TERM LIABILITIES
Long-Term Debt	$13.42M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$789.1K	$1.597M	$1.597M
YoY Change	-90.52%	24.92%	24.92%
Total Long-Term Liabilities	$14.21M	$1.597M	$1.597M
YoY Change	70.76%	24.92%	24.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.02M	$31.37M	$31.37M
Total Long-Term Liabilities	$14.21M	$1.597M	$1.597M
Total Liabilities	$41.23M	$32.97M	$32.50M
YoY Change	25.35%	36.79%	40.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$195.3M	-$190.6M
YoY Change		34.3%
Common Stock	$320.4K	$315.5K
YoY Change		2.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$163.7K	$163.7K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity	-$12.01M	-$11.40M	-$6.830M
YoY Change
Total Liabilities & Shareholders Equity	$33.87M	$25.67M	$25.67M
YoY Change	-32.65%	-48.59%	-48.59%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.008M	-$12.71M	-$45.54M
YoY Change	-69.8%	-29.81%	-25.23%
Depreciation, Depletion And Amortization	$47.65K	$1.240M	$161.9K
YoY Change	-91.02%	256.69%	-81.37%
Cash From Operating Activities	-$2.614M	-$1.969M	-$22.94M
YoY Change	-67.69%	-66.2%	-30.68%
INVESTING ACTIVITIES
Capital Expenditures	$33.66K	$1.771M	$366.6K
YoY Change	-101.42%	-212.2%	-110.85%
Acquisitions			$1.012M
YoY Change
Other Investing Activities	$0.00	$0.00	-$5.013M
YoY Change	-100.0%		22450.16%
Cash From Investing Activities	-$1.812M	-$1.771M	-$13.91M
YoY Change	-75.45%	12.2%	308.72%
FINANCING ACTIVITIES
Cash Dividend Paid	$776.6K		$3.106M
YoY Change	0.0%		256.44%
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$11.99M	1.862M	-$528.2K
YoY Change	-1649.16%	-95.26%	-100.77%
NET CHANGE
Cash From Operating Activities	-$2.614M	-1.969M	-$22.94M
Cash From Investing Activities	-$1.812M	-1.771M	-$13.91M
Cash From Financing Activities	$11.99M	1.862M	-$528.2K
Net Change In Cash	$7.566M	-1.878M	-$37.37M
YoY Change	-146.58%	-105.89%	-216.24%
FREE CASH FLOW
Cash From Operating Activities	-$2.614M	-$1.969M	-$22.94M
Capital Expenditures	$33.66K	$1.771M	$366.6K
Free Cash Flow	-$2.648M	-$3.740M	-$23.30M
YoY Change	-53.76%	-11.95%	-21.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000948320
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	LFMD	Purchase Price Payable PurchasePricePayable		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment		usd
CY2021	LFMD	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration		usd
CY2021	LFMD	Stock Issued During Period Value Cashless Exercise Of Stock Options StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions		usd
CY2022	LFMD	Stock Issued During Period Value Cashless Exercise Of Stock Options StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations		usd
CY2021	LFMD	Sales Returns Reserve SalesReturnsReserve		usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1		usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	LFMD	Stock Issued For Legal Settlement StockIssuedForLegalSettlement		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	49557175	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31887005	shares
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2022	LFMD	Cash Proceeds From Series Preferred And Common Stock Offering CashProceedsFromSeriesPreferredAndCommonStockOffering		usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	LFMD	Purchase Of Membership Interest PurchaseOfMembershipInterest		usd
CY2021	LFMD	Adjustment Of Membership Interest AdjustmentOfMembershipInterest		usd
CY2021	LFMD	Payments To Acquire Productive Asset PaymentsToAcquireProductiveAsset		usd
CY2021	LFMD	Consideration Payable For Cleared Acquisition ConsiderationPayableForClearedAcquisition		usd
CY2021	LFMD	Consideration Payable For Resumebuild Acquisition ConsiderationPayableForResumebuildAcquisition		usd
CY2022	LFMD	Purchase Of Membership Interest In Performance Of Option PurchaseOfMembershipInterestInPerformanceOfOption		usd
CY2022	LFMD	Non Cash Warrants Issued For Debt Instruments NonCashWarrantsIssuedForDebtInstruments		usd
CY2021Q4	LFMD	Purchase Price Payable One PurchasePricePayableOne		usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2021Q4	LFMD	Deferred Tax Asset Software Development DeferredTaxAssetSoftwareDevelopment		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39785
CY2022	dei	Entity Registrant Name EntityRegistrantName	LIFEMD, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0238453
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	236 Fifth Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2022	dei	City Area Code CityAreaCode	(866)
CY2022	dei	Local Phone Number LocalPhoneNumber	351-5907
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022Q4	LFMD	Purchase Price Payable PurchasePricePayable	579319	usd
CY2022Q4	us-gaap	Liabilities Liabilities	32971356	usd
CY2021Q4	us-gaap	Liabilities Liabilities	24104133	usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2021	dei	Auditor Name AuditorName	Friedman LLP
CY2021	dei	Auditor Firm AuditorFirmId	711
CY2022	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2021	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3958957	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41328039	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2834750	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	980055	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	127265	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	203556	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3703363	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1616600	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	687022	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	793190	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11311357	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	44921440	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	476441	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	233805	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1206009	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1752448	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	8840187	usd
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2995789	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3831859	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19761	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	14354496	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5001803	usd
CY2022Q4	us-gaap	Assets Assets	25665853	usd
CY2021Q4	us-gaap	Assets Assets	49923243	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10106793	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9059214	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12166509	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11595605	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2797250	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	63400	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	756093	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	607490	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	5547506	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1499880	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31374151	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22825589	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	574136	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1178544	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	443750	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	100000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4565822	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4110822	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	140	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	140	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31552775	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30704434	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31449735	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30601394	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	315528	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	307045	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	179015250	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164517634	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190562994	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141921085	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	103040	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	103040	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	163701	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	163701	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11395777	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22740033	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-475548	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-1031745	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11871325	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21708288	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25665853	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49923243	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119033520	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92875806	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	18668028	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	17995394	usd
CY2022	us-gaap	Gross Profit GrossProfit	100365492	usd
CY2021	us-gaap	Gross Profit GrossProfit	74880412	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	78369430	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	82541956	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46960782	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39534573	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	8862596	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	6717795	usd
CY2021	us-gaap	Other General Expense OtherGeneralExpense	3317976	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	5033468	usd
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	2838831	usd
CY2022	us-gaap	Development Costs DevelopmentCosts	2970202	usd
CY2021	us-gaap	Development Costs DevelopmentCosts	948157	usd
CY2022	LFMD	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	5101000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	143813273	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	129181493	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-43447781	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-54301081	usd
CY2022	us-gaap	Interest Expense InterestExpense	1275946	usd
CY2021	us-gaap	Interest Expense InterestExpense	3019716	usd
CY2022	LFMD	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	63400	usd
CY2021	LFMD	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	-3995559	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44660327	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61316356	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360700	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7700	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-45021027	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-61324056	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	514632	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-426352	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-45535659	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-60897704	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3106250	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	871476	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48641909	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-61769180	usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.57
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.29
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.57
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.29
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30976455	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27007961	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30976455	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27007961	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4477586	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12071659	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	670750	usd
CY2021	LFMD	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	480609	usd
CY2021	LFMD	Warrants Issued For Debt Instruments WarrantsIssuedForDebtInstruments	6270710	usd
CY2021	LFMD	Sale Of Common Stock In Private Placement Net SaleOfCommonStockInPrivatePlacementNet	13495270	usd
CY2021	LFMD	Sale Of Common Stock Under Atm Net SaleOfCommonStockUnderAtmNet	493481	usd
CY2021	LFMD	Sale Of Series Preferred Stock SaleOfSeriesPreferredStock	33506500	usd
CY2021	LFMD	Stock Issued During Period Value Sale Of Common Stock StockIssuedDuringPeriodValueSaleOfCommonStock	21836427	usd
CY2021	LFMD	Series A Preferred Stock Dividend SeriesAPreferredStockDividend	-871476	usd
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	144000	usd
CY2021	LFMD	Purchase Of Additional Membership Interest Of Worksimpli PurchaseOfAdditionalMembershipInterestOfWorksimpli	-444022	usd
CY2021	LFMD	Adjustment Of Noncontrolling Interest For Additional Investment AdjustmentOfNoncontrollingInterestForAdditionalInvestment	144022	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-61324056	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21708288	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21708288	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13734614	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	90400	usd
CY2022	LFMD	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	38500	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	816000	usd
CY2022	LFMD	Series A Preferred Stock Dividend SeriesAPreferredStockDividend	-3106250	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	144000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	12150	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-45021027	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11871325	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11871325	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-45021027	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-61324056	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2090236	usd
CY2022	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2681807	usd
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	512887	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	926542	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	342310	usd
CY2022	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	273822	usd
CY2022	us-gaap	Depreciation Depreciation	161885	usd
CY2021	us-gaap	Depreciation Depreciation	13560	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	103417	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	57481	usd
CY2022	LFMD	Sales Returns Reserve SalesReturnsReserve	338193	usd
CY2022	LFMD	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	63400	usd
CY2021	LFMD	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	-3995559	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	5101000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	8862596	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	354000	usd
CY2022	LFMD	Operating Lease Payments Adjustments OperatingLeasePaymentsAdjustments	546439	usd
CY2021	LFMD	Operating Lease Payments Adjustments OperatingLeasePaymentsAdjustments	22700	usd
CY2022	LFMD	Stock Issued For Legal Settlement StockIssuedForLegalSettlement	816000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	13734614	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	12071659	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2192888	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-17702	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-76291	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-613209	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2183012	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	409823	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-106168	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	638314	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-455805	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4047626	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	583000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1251037	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-893956	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1309968	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9860357	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-888486	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22935149	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33085489	usd
CY2022	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	8526205	usd
CY2021	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	3132693	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	366633	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	247365	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4000500	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22231	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1012395	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13905733	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3402289	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	13495270	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15000000	usd
CY2021	LFMD	Cash Proceeds From Series Preferred And Common Stock Offering CashProceedsFromSeriesPreferredAndCommonStockOffering	55342927	usd
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	15000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	493481	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	38500	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	480609	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	90400	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	670750	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	3106250	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	871476	usd
CY2021	LFMD	Purchase Of Membership Interest PurchaseOfMembershipInterest	-300000	usd
CY2022	LFMD	Adjustment Of Membership Interest AdjustmentOfMembershipInterest	12150	usd
CY2022	LFMD	Payments To Acquire Productive Asset PaymentsToAcquireProductiveAsset	156250	usd
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	144000	usd
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	144000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2906000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	963965	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	168750	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1494784	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-528200	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68636742	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37369082	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32148964	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41328039	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9179075	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3958957	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41328039	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	189000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	435048	usd
CY2022	LFMD	Cashless Exercise Of Options CashlessExerciseOfOptions	297	usd
CY2021	LFMD	Cashless Exercise Of Options CashlessExerciseOfOptions	8730	usd
CY2022	LFMD	Consideration Payable For Cleared Acquisition ConsiderationPayableForClearedAcquisition	8079367	usd
CY2022	LFMD	Consideration Payable For Resumebuild Acquisition ConsiderationPayableForResumebuildAcquisition	500000	usd
CY2022	LFMD	Principal Of Paycheck Protection Program Loans Forgiven PrincipalOfPaycheckProtectionProgramLoansForgiven	63400	usd
CY2021	LFMD	Principal Of Paycheck Protection Program Loans Forgiven PrincipalOfPaycheckProtectionProgramLoansForgiven	184914	usd
CY2021	LFMD	Purchase Of Membership Interest In Performance Of Option PurchaseOfMembershipInterestInPerformanceOfOption	144022	usd
CY2021	LFMD	Non Cash Warrants Issued For Debt Instruments NonCashWarrantsIssuedForDebtInstruments	6270710	usd
CY2022	LFMD	Right Of Use Asset RightOfUseAsset	89595	usd
CY2021	LFMD	Right Of Use Asset RightOfUseAsset	1752448	usd
CY2022	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	94168	usd
CY2021	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1786034	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_zhFicsTs9zAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_822_z44sgBc7l3I4">NATURE OF THE ORGANIZATION AND BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate History</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD, Inc. was formed in the State of Delaware on May 24, 1994, under its prior name, Immudyne, Inc. The Company changed its name to Conversion Labs, Inc. on June 22, 2018 and then subsequently, on February 22, 2021, it changed its name to LifeMD, Inc. Effective February 22, 2021, the trading symbol for the Company’s common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20210222_ziKzPso0NHok" title="Common stock per share">0.01</span> per share on The Nasdaq Stock Market LLC changed from “CVLB” to “LFMD”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2016, the original operating agreement of Immudyne PR LLC (“Immudyne PR”), a joint venture to market the Company’s immune support, skincare, and hair loss was amended and restated and the Company increased its ownership and voting interest in Immudyne PR to <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20160401__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ImmudynePrLlcMember_zoI2mt1LibHe" title="Equity method investment, ownership percentage">78.2</span>%. Concurrent with the name change of the parent company to Conversion Labs, Inc., Immudyne PR was renamed to Conversion Labs PR LLC. On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety to increase the Company’s ownership and voting interest in Conversion Labs PR to <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ConversionLabsPrMember_z3d7srej14If" title="Equity method investment, ownership percentage">100</span>%. On February 22, 2021, concurrent with the name change of the parent company to LifeMD, Inc., Conversion Labs PR LLC was renamed to LifeMD PR LLC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2018, the Company closed the strategic acquisition of <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20180630__us-gaap--BusinessAcquisitionAxis__custom--LegalSimpliSoftwareLlcMember_zpOWybo5f3s7" title="Voting interests acquired">51</span>% of LegalSimpli Software, LLC, which operates a software as a service application for converting, editing, signing, and sharing PDF documents called PDFSimpli. In addition to LegalSimpli Software, LLC’s growth business model, this acquisition added deep search engine optimization and search engine marketing expertise to the Company. On July 15, 2021, LegalSimpli Software, LLC, changed its name to WorkSimpli Software LLC, (“WorkSimpli”). Effective January 22, 2021, the Company consummated a transaction to restructure the ownership of WorkSimpli (the “WSS Restructuring”) (See Note 8) and concurrently increased its ownership interest in WorkSimpli to <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210122__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LegalSimpliSoftwareLlcMember_ze81zRjN0bd9">85.6</span>%. Effective September 30, 2022, two option agreements were exercised which further restructured the ownership of WorkSimpli. As a result, the Company’s ownership interest in WorkSimpli decreased to <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--LegalSimpliSoftwareLlcMember_zqHmVJl9beIi">73.64</span>%. See Note 8 for additional information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2022, the Company acquired Cleared Technologies, PBC, a Delaware public benefit corporation (“Cleared”), a nationwide allergy telehealth platform that provides personalized treatments for allergy, asthma, and immunology (See Note 3—Acquisitions to our consolidated financial statements included in this report).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nature of Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is a direct-to-patient telehealth company providing patients a high-quality, cost-effective, and convenient way of accessing comprehensive, virtual healthcare. The Company believes the traditional model of visiting a doctor’s office, traveling to a local pharmacy, and returning for follow up care or prescription refills is complex, inefficient, and costly, and discourages many individuals from seeking much needed medical care. The Company is positioned to elevate the healthcare experience through telehealth with our proprietary technology platform, affiliated provider network, broad treatment capabilities, and unique ability to nurture patient relationships. Direct-to-patient telehealth technology companies, like the Company, connect consumers to affiliated, licensed, healthcare professionals for care across numerous indications, including urgent and primary care, men’s and women’s health, and dermatology, chronic care management and more.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s telehealth platform helps patients access their licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis. In addition to its telehealth prescription offerings, the Company sells over-the-counter (“OTC”) products. All products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. This creates convenience and often discounted pricing opportunities for patients and recurring revenue streams for the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With its first brand, ShapiroMD, the Company has built a full line of proprietary OTC products for male and female hair loss—including Food and Drug Administration (“FDA”) approved OTC minoxidil and an FDA-cleared medical device—and now a personalized telehealth platform offering that gives consumers access to virtual medical treatment from their providers and, when appropriate, a full line of oral and topical prescription medications for hair loss. The Company’s men’s brand, RexMD, currently offers access to provider-based treatment for erectile dysfunction, as well as treatment for other common men’s health issues, including premature ejaculation and hair loss. In the first quarter of 2021, the Company launched NavaMD, a tele-dermatology and skincare brand for women. The Company has built a platform that allows it to efficiently launch telehealth and wellness product lines wherever it determines there is a market need.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business and Subsidiary History</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In early 2019, the Company launched a service-based business under the name Conversion Labs Media LLC (“CVLB Media”), a Puerto Rico limited liability company. However, this business initiative was terminated in early 2019. In May 2019, Conversion Labs Rx, LLC (“CVLB Rx”), a Puerto Rico limited liability company, signed a strategic partnership agreement with Specialty Medical Drugstore, Inc. (doing business as “GoGoMeds”). However, since its inception, CVLB Rx did not conduct any business and CVLB Rx was dissolved on August 7, 2020. Additionally, Conversion Labs Asia Limited (“Conversion Labs Asia”), a Hong Kong company, had no activity during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2022, the Company acquired Cleared, a nationwide allergy telehealth platform that provides personalized treatments for allergy, asthma, and immunology. Under the terms of the agreement, the Company acquired all outstanding shares of Cleared at closing in exchange for a $<span id="xdx_902_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn3n3_c20220117__20220118_zwBvE100m2Gi" title="Payments to acquire businesses, net of cash acquired">460</span> thousand upfront cash payment, and two non-contingent milestone payments for a total of $<span id="xdx_901_ecustom--MileStonePayment_pn4n6_c20220117__20220118_zceUBWjd0jhb" title="Milestone payments">3.46</span> million ($<span id="xdx_90D_ecustom--MileStonePayment_pn4n6_c20220117__20220118__srt--StatementScenarioAxis__custom--SecondAnniversariesMember_z2y5yR3Z2QDh" title="Milestone payments">1.73 </span>million each on or before the first and second anniversaries of the closing date). The Company purchased a convertible note from a strategic pharmaceutical investor for $<span id="xdx_906_eus-gaap--ConversionOfStockAmountConverted1_pn3n3_c20220117__20220118_zKOOnYHHk7pe" title="Conversion of stock converted">507</span> thousand which was converted upon closing of the Cleared acquisition. The Company also agreed to a performance-based earnout based on Cleared’s future net sales, payable in cash or shares at the Company’s discretion. On February 4, 2023, the Company entered into the First Amendment to the Stock Purchase Agreement (the “First Amendment”) between the Company and the sellers of Cleared. The First Amendment was amended to, among other things: (i) reduce the total purchase price by $<span id="xdx_903_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn3n3_c20230204__20230204__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3sNhWG0fzL" title="Payments to acquire businesses, net of cash acquired">250</span> thousand to a total of $<span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pn2n6_c20230204__20230204__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zysGojPAGc1h" title="Payments to acquire businesses, net of cash acquired">3.67</span> million; (ii) change the timing of the payment of the purchase price to $<span id="xdx_905_eus-gaap--PaymentsToAcquireBusinessesGross_pn3n3_c20230204__20230204__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCrZJZjjPlY7" title="Payments to acquire businesses, gross">460</span> thousand paid at closing (which has already been paid by the Company), with the remaining amount to be paid in five quarterly installments beginning on or before February 6, 2023 and ending January 15, 2024; (iii) removing all “earn-out” payments payable by the Company to the sellers; and (iv) remove certain representations and warranties of the Company and sellers in connection with the transaction (See Note 3—Acquisitions to our consolidated financial statements included in this report).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, WorkSimpli closed on an Asset Purchase Agreement (the “ResumeBuild APA”) with East Fusion FZCO, a Dubai, UAE corporation (the “Seller”), whereby WorkSimpli acquired substantially all of the assets associated with the Seller’s business, offering subscription-based resume building software through software as a service online platforms (the “Acquisition”). WorkSimpli paid $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z7gVi0weEvna" title="Consideration paid">4.0</span> million to the Seller upon closing. The Seller is also entitled to a minimum of $<span id="xdx_907_ecustom--BusinessAcquisitionPeriodicPayments_pn3n3_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_znab1QQVrJga" title="Business acquisition periodic payments">500</span> thousand to be paid out in quarterly payments equal to the greater of <span id="xdx_901_ecustom--PercentageOfPaymentAcquistion_pid_dp_uPure_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zWejd0D97xJb" title="Percentage of payment acquistion">15</span>% of net profits (as defined in the ResumeBuild APA) or $<span id="xdx_90C_ecustom--AssetAcquisitionClosing_c20220201__20220228_zPqtwB4nPTu2" title="Asset acquisition closing">62,500</span>, for a two-year period ending on the two-year anniversary of the closing of the Acquisition. WorkSimpli borrowed the purchase price from the Company pursuant to a promissory note with the obligation secured by an equity purchase guarantee agreement and a stock option pledge agreement from Fitzpatrick Consulting, LLC and its sole member Sean Fitzpatrick, who is Co-Founder and President of WorkSimpli (See Note 3—Acquisitions to our consolidated financial statements included in this report).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, the terms “LifeMD,” “Company,” “we,” “us,” and “our” refer to LifeMD, Inc. (formerly known as Conversion Labs, Inc.), our wholly subsidiary LifeMD PR LLC (formerly Immudyne PR LLC, and “Conversion Labs PR”), a Puerto Rico limited liability company (“Conversion Labs PR”, or “CLPR”), Cleared, a Delaware public benefit corporation and our majority-owned subsidiary, WorkSimpli. The affiliated network of medical Professional Corporations and medical Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C., (“LifeMD PC”) is the Company’s affiliated, variable interest entity in which we hold a controlling financial interest. Unless otherwise specified, all dollar amounts are expressed in United States dollars.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity & Going Concern Evaluation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has funded operations in the past through the sales of its products, issuance of common and preferred stock, and through loans and advances. The Company’s continued operations are dependent upon obtaining an increase in its sale volumes and obtaining funding from third-party sources or the issuance of additional shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company has an accumulated deficit approximating $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zklizyjHE1Bk" title="Accumulated deficit">190.6</span> million and has experienced significant losses from its operations. To date, the Company has been funding operations primarily through the sales of its products, sale of equity in private placements and securities purchased by a financial institution. There can be no assurances that we will be successful in increasing revenues, improving operational efficiencies or that financing will be available or, if available, that such financing will be available under favorable terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a current cash balance of approximately $<span id="xdx_90D_eus-gaap--Cash_iI_pn5n6_c20221231_zNIKHWEI3HXd" title="Cash">14.6</span> million as of the filing date. The Company reviewed its forecasted operating results and sources and uses of cash used in management’s assessment, which included the available financing and consideration of positive and negative evidence impacting management’s forecasts, market, and industry factors. The Company’s continuance as a going concern is highly dependent on its future profitability and on the on-going support of its stockholders, affiliates, and creditors. Based on these circumstances, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has begun to implement strategies to strengthen revenues and improve operational efficiencies across the business and is significantly curtailing expenses, however, these strategies do not mitigate the substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, on June 8, 2021, the Company filed a shelf registration statement on Form S-3 under the Securities Act, which was declared effective on June 22, 2021 (the “2021 Shelf”). Under the 2021 Shelf at the time of effectiveness, the Company had the ability to raise up to $<span id="xdx_903_eus-gaap--DebtSecurities_iI_pn6n6_c20210608__us-gaap--StatementEquityComponentsAxis__custom--SharesAndSecuritiesMember_zuR4wxB8bUM" title="Raise up funds">150</span> million by selling common stock, preferred stock, debt securities, warrants, and units. In conjunction with the 2021 Shelf, the Company also entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc. and Cantor Fitzgerald & Co. relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company may, but is not obligated to, offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20210607__20210608_zPbRSBsdxZM4" title="Issuance of private placement">60</span> million, through or to the Agents, acting as agent or principal. Sales of common stock, if any, will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act. As of December 31, 2022, the Company has $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ATMSalesAgreementMember_zKJMVWmKEP7" title="Proceeds from sale of securities">59.5</span> million available under the ATM Sales Agreement and $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ShelfAgreementMember_zBGS5fKc9La3" title="Proceeds from sale of securities">32</span> million available under the 2021 Shelf.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management believes that the overall market value of the telehealth industry is positive and that it will continue to drive interest in the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	460000	usd
CY2022Q1	LFMD	Mile Stone Payment MileStonePayment	3460000	usd
CY2022Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	507000	usd
CY2022Q1	LFMD	Asset Acquisition Closing AssetAcquisitionClosing	62500	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190600000	usd
CY2022Q4	us-gaap	Cash Cash	14600000	usd
CY2021Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	60000000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	160898	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	57481	usd
CY2021Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zERdWsf0Ee16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the valuation of inventory, stockholders’ equity-based transactions, estimates to cash flow projections, and liquidity assessment. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zDrZiU6oXAfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reclassifications</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to conform the prior year’s data to the current presentation. These reclassifications have no effect on previously reported operating loss, stockholders’ deficit, or cash flows. Given the increase in the Company’s software business and to conform the Company’s presentation of operating results to industry standards, the Company has changed their categories for reporting operations and, as a result, the Company has made reclassifications to the prior year presentation in order to conform it to the current periods’ presentation. The reclassifications include: (1) $<span id="xdx_90D_eus-gaap--DevelopmentCosts_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--OtherOperatingExpenseMember_zGvpQa14YcLj" title="Development costs">169,385</span> of development services costs reclassified from other operating expenses to development costs and (2) $<span id="xdx_903_eus-gaap--LeaseCost_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--OtherOperatingExpenseMember_zgZ6qTYbNr31" title="Lease expense">35,165</span> of lease expenses reclassified from general and administrative expenses to other operating expenses, for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	LFMD	Subscription Price Per Share SubscriptionPricePerShare	1.95
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5500000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1500000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119033520	usd
CY2022	LFMD	Concentration Risk Percentage ConcentrationRiskPercentage	1	pure
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92875806	usd
CY2021	LFMD	Concentration Risk Percentage ConcentrationRiskPercentage	1	pure
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1499880	usd
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	916880	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	37410617	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	23430037	usd
CY2022	LFMD	Revenue Recognized RevenueRecognized	33362991	usd
CY2021	LFMD	Revenue Recognized RevenueRecognized	22847037	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	5547506	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1499880	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	815000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	477000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2587370	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1592654	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1276891	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	81427	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	160898	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	57481	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3703363	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1616600	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	127000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	204000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	399000	usd
CY2022Q4	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	12100000	usd
CY2021Q4	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	3600000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	827000	usd
CY2022	LFMD	Principal Of Paycheck Protection Program Loans Forgiven PrincipalOfPaycheckProtectionProgramLoansForgiven	63400	usd
CY2021	LFMD	Principal Of Paycheck Protection Program Loans Forgiven PrincipalOfPaycheckProtectionProgramLoansForgiven	184914	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10766676	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10385914	shares
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zqD7CKQ60eaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentrations of Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits. We are dependent on certain third-party manufacturers and pharmacies, although we believe that other contract manufacturers or third-party pharmacies could be quickly secured if any of our current manufacturers or pharmacies cease to perform adequately. As of December 31, 2022, we utilized four (4) suppliers for fulfillment services, six (6) suppliers for manufacturing finished goods, five (5) suppliers for packaging, bottling, and labeling, and three (3) suppliers for prescription medications. As of December 31, 2021, we utilized four (4) suppliers for fulfillment services, six (6) suppliers for manufacturing finished goods and four (4) suppliers for packaging, bottling and labeling.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2022Q1	LFMD	Business Combination Consideration Transferred BusinessCombinationConsiderationTransferred	9100000	usd
CY2022Q1	LFMD	Business Combination Cash Paid Upfront BusinessCombinationCashPaidUpfront	1000000.0	usd
CY2022Q1	LFMD	Business Combination Future Payable BusinessCombinationFuturePayable	3000000.0	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	5100000	usd
CY2022Q1	LFMD	Business Combination Potential Earn Out BusinessCombinationPotentialEarnOut	72800000	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9091762	usd
CY2022Q1	LFMD	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Customer Relationship Intangible Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationshipIntangibleAsset	918812	usd
CY2022Q1	LFMD	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Name Intangible Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeNameIntangibleAsset	133339	usd
CY2022Q1	LFMD	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Developed Technology Intangible Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopedTechnologyIntangibleAsset	12920	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	7168	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	37888	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets	354000	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	408030	usd
CY2022Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	8035665	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	8000000.0	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	5100000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8000000.0	usd
CY2022Q1	LFMD	Percentage Of Payment Acquistion PercentageOfPaymentAcquistion	0.15	pure
CY2022Q1	LFMD	Asset Acquisition Closing AssetAcquisitionClosing	62500	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2043971	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1209310	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3831859	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19761	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	926542	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	342310	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3508883	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	4981453	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2501035	usd
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2000000	usd
CY2022Q4	LFMD	Purchase Price Payable One PurchasePricePayableOne	2463002	usd
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	776563	usd
CY2021Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	871476	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	576027	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1657843	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	448718	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1892281	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2084833	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12166509	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11595605	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.324	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0080	pure
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	LFMD	Undesignated Preferred Stock UndesignatedPreferredStock	3385000	shares
CY2021Q2	us-gaap	Substantial Doubt About Going Concern Managements Plans Substantial Doubt Alleviated SubstantialDoubtAboutGoingConcernManagementsPlansSubstantialDoubtAlleviated	Under the 2021 Shelf at the time of effectiveness, the Company had the ability to raise up to $150 million by selling common stock, preferred stock, debt securities, warrants and units. In conjunction with the 2021 Shelf, the Company also entered into the ATM Sales Agreement whereby the Company may offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $60 million.
CY2021Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	60000000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	58500000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	55300000	usd
CY2022	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	2.21875
CY2022	LFMD	Percentage Of Preferred Stock Liquidation Preference PercentageOfPreferredStockLiquidationPreference	0.08875	pure
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The Series A Preferred Stock is perpetual and has no maturity date. The Series A Preferred Stock will be redeemable at our option, in whole or in part, at the following redemption prices, plus any accrued and unpaid dividends up to, but not including, the date of redemption: 1) on and after October 15, 2022 and prior to October 15, 2023, at a redemption price equal to $25.75 per share, 2) on and after October 15, 2023 and prior to October 15, 2024, at a redemption price equal to $25.50 per share, 3) on and after October 15, 2024 and prior to and prior to October 15, 2025 at a redemption price equal to $25.25 per share and 4) on and after October 15, 2025 at a redemption price equal to $25.00 per share. In addition, upon the occurrence of a delisting event or change of control, we may, subject to certain conditions, at our option, redeem the Series A Preferred Stock, in whole or in part within 90 days after the first date on which such delisting event occurred or within 120 days after the first date on which such change of control occurred, as applicable, by paying $25.00 per share, plus any accumulated and unpaid dividends up to, but not including, the redemption date.
CY2022Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	25.00
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	90400	shares
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	90400	usd
CY2022	LFMD	Cashless Exercise Of Options Shares CashlessExerciseOfOptionsShares	29691	shares
CY2022	LFMD	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	22000	shares
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	38500	usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	375000	shares
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	670750	usd
CY2021	LFMD	Cashless Exercise Of Options Shares CashlessExerciseOfOptionsShares	873047	shares
CY2021	LFMD	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	162033	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	480609	usd
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	306250	shares
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	400000	shares
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1347875	shares
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	823350	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	523206	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	68850	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	85177	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1330229	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	871344	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	47565	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	773952	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	392241	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M25D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0715	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0715	pure
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2022	us-gaap	Short Term Lease Payments ShortTermLeasePayments	2700	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	3000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	399000	usd
CY2021Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	5-for-1
CY2021Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	5-for-1
CY2021Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	5-for-1
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	400000	shares
CY2022	LFMD	Number Of Additional Shares Issued NumberOfAdditionalSharesIssued	100000	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	400000	shares
CY2022	LFMD	Number Of Additional Shares Issued NumberOfAdditionalSharesIssued	100000	shares
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	94300000	usd
CY2022	LFMD	Operating Loss Carryforwards Expiration Description OperatingLossCarryforwardsExpirationDescription	the net operating loss carryforwards will expire in 2023 if not utilized prior, and will continue to expire during various years through 2038
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11800000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20800000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6700	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7700	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	6700	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	7700	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1719000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1365000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	354000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360700	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7700	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2022	LFMD	Expected Tax Expense Benefit ExpectedTaxExpenseBenefit	-9474000	usd
CY2021	LFMD	Expected Tax Expense Benefit ExpectedTaxExpenseBenefit	-12684000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-714000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-618000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	730000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-52000	usd
CY2022	LFMD	Effective Income Tax Rate Reconciliation Tax Apportionment Of Puerto Rico Income EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome	-108000	usd
CY2021	LFMD	Effective Income Tax Rate Reconciliation Tax Apportionment Of Puerto Rico Income EffectiveIncomeTaxRateReconciliationTaxApportionmentOfPuertoRicoIncome	76000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9973000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13192000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-46300	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	93700	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360700	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7700	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11646000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6899000	usd
CY2022Q4	LFMD	Deferred Tax Asset Software Development DeferredTaxAssetSoftwareDevelopment	-142000	usd
CY2022Q4	LFMD	Deferred Tax Assets Temporary Differences DeferredTaxAssetsTemporaryDifferences	-2389000	usd
CY2021Q4	LFMD	Deferred Tax Assets Temporary Differences DeferredTaxAssetsTemporaryDifferences	-1201000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21382000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15673000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35559000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23773000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35559000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23773000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119033520	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92875806	usd
CY2022	LFMD	Gross Margin GrossMargin	0.843	pure
CY2021	LFMD	Gross Margin GrossMargin	0.806	pure
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-43447781	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-54301081	usd
CY2022Q4	us-gaap	Assets Assets	25665853	usd
CY2021Q4	us-gaap	Assets Assets	49923243	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
lfmd-20221231_cal.xml	Edgar Link	unprocessable
0001493152-23-008560-index-headers.html	Edgar Link	pending
0001493152-23-008560-index.html	Edgar Link	pending
0001493152-23-008560.txt	Edgar Link	pending
0001493152-23-008560-xbrl.zip	Edgar Link	pending
ex10-82.htm	Edgar Link	pending
ex10-83.htm	Edgar Link	pending
ex10-84.htm	Edgar Link	pending
ex10-84_001.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
ex3-1_004.jpg	Edgar Link	pending
ex3-1_005.jpg	Edgar Link	pending
ex3-1_006.jpg	Edgar Link	pending
ex3-1_007.jpg	Edgar Link	pending
ex3-1_008.jpg	Edgar Link	pending
ex3-1_009.jpg	Edgar Link	pending
ex3-1_010.jpg	Edgar Link	pending
ex3-1_011.jpg	Edgar Link	pending
ex3-1_012.jpg	Edgar Link	pending
ex3-1_013.jpg	Edgar Link	pending
ex3-1_014.jpg	Edgar Link	pending
ex3-1_015.jpg	Edgar Link	pending
ex3-1_016.jpg	Edgar Link	pending
ex3-1_017.jpg	Edgar Link	pending
ex3-1_018.jpg	Edgar Link	pending
ex3-1_019.jpg	Edgar Link	pending
ex3-1_020.jpg	Edgar Link	pending
ex3-1_021.jpg	Edgar Link	pending
ex3-1_022.jpg	Edgar Link	pending
ex3-1_023.jpg	Edgar Link	pending
ex3-1_024.jpg	Edgar Link	pending
ex3-1_025.jpg	Edgar Link	pending
ex3-1_026.jpg	Edgar Link	pending
ex3-1_027.jpg	Edgar Link	pending
ex3-1_028.jpg	Edgar Link	pending
ex3-1_029.jpg	Edgar Link	pending
ex3-1_030.jpg	Edgar Link	pending
ex3-1_031.jpg	Edgar Link	pending
ex3-1_032.jpg	Edgar Link	pending
ex3-1_033.jpg	Edgar Link	pending
ex3-1_034.jpg	Edgar Link	pending
ex3-1_035.jpg	Edgar Link	pending
ex3-1_036.jpg	Edgar Link	pending
ex3-1_037.jpg	Edgar Link	pending
ex3-1_038.jpg	Edgar Link	pending
ex3-1_039.jpg	Edgar Link	pending
ex3-1_040.jpg	Edgar Link	pending
ex3-1_041.jpg	Edgar Link	pending
ex3-1_042.jpg	Edgar Link	pending
ex3-1_043.jpg	Edgar Link	pending
ex3-1_044.jpg	Edgar Link	pending
ex3-1_045.jpg	Edgar Link	pending
ex3-1_046.jpg	Edgar Link	pending
ex3-1_047.jpg	Edgar Link	pending
ex3-1_048.jpg	Edgar Link	pending
ex3-1_049.jpg	Edgar Link	pending
ex3-1_050.jpg	Edgar Link	pending
ex3-1_051.jpg	Edgar Link	pending
ex3-1_052.jpg	Edgar Link	pending
ex3-1_053.jpg	Edgar Link	pending
ex3-1_054.jpg	Edgar Link	pending
ex3-1_055.jpg	Edgar Link	pending
ex3-1_056.jpg	Edgar Link	pending
ex3-1_057.jpg	Edgar Link	pending
ex3-1_058.jpg	Edgar Link	pending
ex3-1_059.jpg	Edgar Link	pending
ex3-1_060.jpg	Edgar Link	pending
ex3-1_061.jpg	Edgar Link	pending
ex3-1_062.jpg	Edgar Link	pending
ex3-1_063.jpg	Edgar Link	pending
ex3-1_064.jpg	Edgar Link	pending
ex3-1_065.jpg	Edgar Link	pending
ex3-1_066.jpg	Edgar Link	pending
ex3-1_067.jpg	Edgar Link	pending
ex3-1_068.jpg	Edgar Link	pending
ex3-1_069.jpg	Edgar Link	pending
ex3-1_070.jpg	Edgar Link	pending
ex3-1_071.jpg	Edgar Link	pending
ex3-1_072.jpg	Edgar Link	pending
ex3-1_073.jpg	Edgar Link	pending
ex3-1_074.jpg	Edgar Link	pending
ex3-1_075.jpg	Edgar Link	pending
ex3-1_076.jpg	Edgar Link	pending
ex3-1_077.jpg	Edgar Link	pending
ex3-1_078.jpg	Edgar Link	pending
ex3-1_079.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
lfmd-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
lfmd-20221231_def.xml	Edgar Link	unprocessable
lfmd-20221231_lab.xml	Edgar Link	unprocessable
lfmd-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LFMD
LifeMD, Inc. Stock $lfmd

2023 Q1 Form 10-K Financial Statement

#000149315223008560 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFMD LifeMD, Inc. Stock $lfmd

2023 Q1 Form 10-K Financial Statement

#000149315223008560 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFMD
LifeMD, Inc. Stock $lfmd